Florida-based AIM ImmunoTech Inc. is a prominent player in the immuno-pharma sector, with a focus on developing therapies to combat a range of cancers, viral diseases and immune-deficiency disorders. Its flagship product is Ampligen, a drug composed of macromolecular ribonucleic acid molecules that is designed to treat chronic fatigue syndrome, and the company is also developing it for use against an extensive list of conditions including not only Hepatitis B and HIV but also COVID-19 and post-COVID conditions. Additionally, AIM provides Alferon N Injection, an injectable formulation of natural alpha interferon that serves as a treatment option for sexually transmitted disease genital warts caused by the human papilloma virus. The company is supported in its mission by agreements with expert industry players such as Amarex Clinical Research LLC, Polysciences Inc., and the University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. AIM ImmunoTech began its journey under the name Hemispherx Biopharma, Inc. in 1966 and changed to its present identity in August 2019 to reflect its renewed focus on the field of immuno-pharma.